CTOs on the Move


 
At Vyriad, we are developing the next generation of targeted cancer therapies using engineered viruses that selectively attack cancer cells and ignite robust immune responses to prevent cancer recurrence.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million
  • www.vyriad.com
  • 2900 37th Street NW Building 110
    Rochester, MN USA 55901
  • Phone: 507.289.0944

Executives

Name Title Contact Details

Funding

Vyriad raised $24.3M on 11/22/2019

Similar Companies

TandemAI

TandemAI is an advanced technology company dedicated to reinventing drug discovery infrastructure. The company integrates proprietary AI-driven, high-performance computation with its efficient, large-scale in-house wet lab operations to deliver a turnkey drug discovery solution. TandemAI has built its networked platform from the ground up in the U.S. and China to increase the speed of drug discovery and deliver cost-effective opportunities to its partners and to the global scientific community.

GeneData

GeneData is a Lexington, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Actinium Pharmaceuticals

Actinium Pharmaceuticals is a New York, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Breonics

Breonics is a Otisville, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Impact Biomedicines

Impact Biomedicines, Inc. (Impact) is pioneering the development of life-changing treatments for patients with myeloproliferative neoplasms and other cancers. Led by a highly skilled and devoted team, Impact is advancing a late-stage pipeline centered around fedratinib, a potent and highly selective oral small molecule JAK2 kinase inhibitor, which is being developed initially for the treatment of myelofibrosis (MF) and polycythemia vera (PV). Impact was formed in 2016 after acquisition of Sanofi’s full rights for the global development and commercialization of fedratinib. The Impact team intends to pursue multiple clinical indications for fedratinib to maximize its potential as a best-in-class therapy for JAK2-dependent diseases.